Unum Therapeutics (NASDAQ:UMRX) had its target price reduced by investment analysts at Wedbush from $20.00 to $13.00 in a note issued to investors on Tuesday, The Fly reports. The firm presently has an “outperform” rating on the stock. Wedbush also issued estimates for Unum Therapeutics’ Q3 2019 earnings at ($0.30) EPS, Q4 2019 earnings at ($0.23) EPS, FY2019 earnings at ($1.27) EPS, FY2020 earnings at ($0.83) EPS, FY2021 earnings at ($1.39) EPS, FY2022 earnings at ($1.17) EPS and FY2023 earnings at $0.04 EPS. The analysts noted that the move was a valuation call.
A number of other analysts also recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Unum Therapeutics in a research report on Tuesday. SunTrust Banks dropped their price objective on Unum Therapeutics to $6.00 and set a “buy” rating for the company in a research report on Wednesday, July 3rd. Zacks Investment Research upgraded Unum Therapeutics from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Friday, April 26th. Finally, ValuEngine upgraded Unum Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Unum Therapeutics presently has a consensus rating of “Buy” and an average price target of $12.40.
NASDAQ:UMRX opened at $1.81 on Tuesday. The firm’s fifty day moving average is $2.23. The company has a market cap of $53.91 million, a P/E ratio of -1.30 and a beta of 1.38. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.11. Unum Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $16.72.
Hedge funds have recently modified their holdings of the company. Rhumbline Advisers purchased a new position in Unum Therapeutics during the 1st quarter valued at about $85,000. Acadian Asset Management LLC grew its holdings in shares of Unum Therapeutics by 134.8% during the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock worth $85,000 after acquiring an additional 18,717 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Unum Therapeutics by 251.5% during the 4th quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock worth $204,000 after acquiring an additional 33,091 shares during the period. Jane Street Group LLC purchased a new position in shares of Unum Therapeutics during the 2nd quarter worth approximately $132,000. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Unum Therapeutics by 7.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 54,956 shares of the company’s stock worth $242,000 after acquiring an additional 3,846 shares during the period. 47.16% of the stock is owned by institutional investors.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Featured Story: Trading Stocks – What are percentage gainers?
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.